Lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-14. Anything still debated is marked as such rather than presented as settled.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
==== 2009 ==== A top-level Georgian official suspected in February 2009 that there was a connection between one German expert working for Tagliavini and Russian Gazprom-affiliated companies. In October 2009, an anonymous source told the news agency that Gazprom paid German expert. The news agency alleged that German Foreign Minister Frank-Walter Steinmeier was promised a job at Gazprom for his influence on the report. Germany was the largest trade partner of Russia as of August 2008. In September 2009, before the report was published, former Prime Minister of Estonia Mart Laar said in an interview that the commission forgot "that during the war, no Georgian soldier, no plane, no other military equipment left the legal, internationally recognized territory of Georgia. It was Georgian territory, and no Georgian soldier [left] the borders of Georgia." After the publication of the report, Laar stated that the report stated that Russian accusation of genocide was false. However, the commission did not declare Russia as aggressor, because Europe would have to hold tribunal on the Russian war crimes. Before the report was published, Russian Foreign Ministry spokesman Igor Lyakin-Frolov said Russian authorities had been "absolutely fair and honest" during investigation. He did not doubt neutrality of the report and hoped that the blame would be pinned on Ukraine for arming Georgia; however, he also stated it would be "unfair" if both Russia and Georgia were found guilty. After the report was published, Russian and South Ossetian officials mostly approved of the report.
Chemical: In addition to dead organic matter, the earthworm also ingests any other soil particles that are small enough, including sand grains up to 1⁄20 inch (1.3 mm), into its gizzard, wherein those minute fragments of grit (gastroliths) grind everything into a fine paste which is then digested in the intestine, increased surface area favouring microbial colonization and enzymatic action. When the worm excretes this paste in the form of casts, deposited on the surface or deeper in the soil, carbon, nitrogen and phosphorus are increased compared to the bulk soil and nutrients are changed to a plant-available form, increasing locally soil fertility. In conditions where humus is plentiful, the weight of casts produced may be greater than 4.5 kilograms (9.9 lb) per worm per year. Physical: The earthworm's burrowing creates a multitude of channels through the soil and is of great value in maintaining the soil structure, enabling processes of aeration and drainage. Permaculture co-founder Bill Mollison points out that by sliding in their tunnels, earthworms "act as an innumerable army of pistons pumping air in and out of the soils on a 24-hour cycle (more rapidly at night)". Thus, the earthworm not only creates passages for air and water to traverse the soil, i.e. increases soil porosity, but also as a soil engineer its bioturbation activities modify the vital organic component that makes a soil healthy. Earthworms promote the formation of nutrient-rich casts that have high soil aggregation (good soil structure) and soil fertility and quality.
=== Discovery of the role of yeast === The French chemist Louis Pasteur founded zymology in 1856 when he connected yeast to fermentation. In studying the conversion of sugar to alcohol by yeast, Pasteur concluded that the fermentation was catalyzed by a vital force, called "ferments", within the yeast cells. The "ferments" were thought to function only within living organisms. Pasteur wrote that "Alcoholic fermentation is an act correlated with the life and organization of the yeast cells, not with the death or putrefaction of the cells."
The following is a list of notable proteins that are produced from recombinant DNA, using biomolecular engineering. In many cases, recombinant human proteins have replaced the original animal-derived version used in medicine. The prefix "rh" for "recombinant human" appears less and less in the literature. A much larger number of recombinant proteins is used in the research laboratory. These include both commercially available proteins (for example most of the enzymes used in the molecular biology laboratory), and those that are generated in the course specific research projects.
==== Characterization of synthetic carbon clusters ==== Another application of direct insertion EI-MS is the characterization of novel synthetic carbon clusters isolated in the solid phase. These crystalline materials consist of C60 and C70 in the ratio of 37:1. In one investigation it has been shown that the synthetic C60 molecule is remarkably stable and that it retains its aromatic character.
Sources: en.wikipedia.org
=== Maintaining translational accuracy === EF-Tu contributes to translational accuracy in three ways. In translation, a fundamental problem is that near-cognate anticodons have similar binding affinity to a codon as cognate anticodons, such that anticodon-codon binding in the ribosome alone is not sufficient to maintain high translational fidelity. This is addressed by the ribosome not activating the GTPase activity of EF-Tu if the tRNA in the ribosome's A-site does not match the mRNA codon, thus preferentially increasing the likelihood for the incorrect tRNA to leave the ribosome. Additionally, regardless of tRNA matching, EF-Tu also induces a delay after freeing itself from the aa-tRNA, before the aa-tRNA fully enters the A-site (a process called accommodation). This delay period is a second opportunity for incorrectly charged aa-tRNAs to move out of the A-site before the incorrect amino acid is irreversibly added to the polypeptide chain. A third mechanism is the less well understood function of EF-Tu to crudely check aa-tRNA associations and reject complexes where the amino acid is not bound to the correct tRNA coding for it.
Task Force 1–41 Infantry was the first coalition force to breach the Saudi Arabian border on 15 February 1991 and conduct ground combat operations in Iraq engaging in direct and indirect fire fights with the enemy on 17 February 1991. Prior to this action the Task Force's primary fire support battalion, 4th Battalion of the 3rd Field Artillery Regiment, participated in a massive artillery preparation. Around 300 guns from multiple countries participated in the artillery barrage. Over 14,000 rounds were fired during these missions. M270 Multiple Launch Rocket Systems contributed an additional 4,900 rockets fired at Iraqi targets. Iraq lost close to 22 artillery battalions during the initial stages of this barrage, including the destruction of approximately 396 Iraqi artillery pieces. By the end of these raids Iraqi artillery assets had all but ceased to exist. One Iraqi unit that was totally destroyed during the preparation was the Iraqi 48th Infantry Division Artillery Group. The group's commander stated his unit lost 83 of its 100 guns to the artillery preparation. The artillery bombardment was supplemented by Boeing B-52 Stratofortress bombing raids and Lockheed AC-130 attacks. AH-64 Apache attack helicopters from the 1st Infantry Division and B-52 bombers attacked the Iraqi 110th Infantry Brigade. Under enemy fire, the 1st and 9th Engineer Battalions marked and proofed assault lanes to secure a foothold in enemy territory and pass the 1st Infantry Division and the 1st Armoured Division forward.
When they pupate, they attach to the undersides of leaves and form a silky cocoon. This stage can last 4–13 days, depending on the temperature of the environment. Male pupae are slightly larger than female.
== Advocacy == Breakthrough T1D advocates for federally funded T1D research, facilitates the delivery of medical advancements and resources to the T1D community, and supports policies that help prevent, manage, and treat T1D, with an aim toward eventual development of a cure. Breakthrough T1D has advocated for various kinds of research; in a 2004 article in The Wall Street Journal, the authors observed that the Breakthrough T1D "... has become adept at unleashing an army of hard-to-resist lobbyists – made up of determined parents and their afflicted children – on researchers, politicians and potential donors."
Technology & commerce: Home to the Rajiv Gandhi IT Park, which houses campuses for Infosys, Tech Mahindra, and Airtel. It also features Asia's largest motor market and major shopping centers like Fun Republic and DT Mall. Residential & facilities: The area contains a mix of urban societies (Uppal's Marble Arch, Rajeev Vihar) and traditional localities (Mari Wala Town, Pipliwala Town). It is supported by the Kalagram cultural center, The Lalit 5-star hotel, and several prominent schools including RIMT World School and Gurukul Global.
Sources: en.wikipedia.org
The pentose phosphate pathway (also called the phosphogluconate pathway and the hexose monophosphate shunt and abbreviated as PPP) is a metabolic pathway parallel to glycolysis. It generates NADPH and pentoses (five-carbon sugars) as well as ribose 5-phosphate, a precursor for the synthesis of nucleotides. While the pentose phosphate pathway does involve oxidation of glucose, its primary role is anabolic rather than catabolic. The pathway is especially important in red blood cells (erythrocytes). The reactions of the pathway were elucidated in the early 1950s by Bernard Horecker and co-workers. There are two distinct phases in the pathway. The first is the oxidative phase, in which NADPH is generated, and the second is the non-oxidative synthesis of five-carbon sugars. For most organisms, the pentose phosphate pathway takes place in the cytosol; in plants, most steps take place in plastids. Like glycolysis, the pentose phosphate pathway appears to have a very ancient evolutionary origin. The reactions of this pathway are mostly enzyme catalyzed in modern cells, however, they also occur non-enzymatically under conditions that replicate those of the Archean ocean, and are catalyzed by metal ions, particularly ferrous ions (Fe(II)). This suggests that the origins of the pathway could date back to the prebiotic world.
THC is widely used as a recreational drug, both by itself or with other cannabinoids like cannabidiol (CBD) or in the form of cannabis. It is the main psychoactive constituent in cannabis. The effects of THC include euphoria, appetite stimulation, sedation, cognitive and memory impairment, pain relief, anxiety, and reduced body temperature. THC can produce strong hallucinogenic effects, mystical experiences, and psychosis-like reactions at high doses in a subset of individuals. These hallucinogenic effects are distinct from but potentially just as strong as or even stronger than those of other hallucinogens like serotonergic psychedelics, dissociatives, and salvia. Besides the hallucinogenic effects, high doses of THC can also produce effects including anxiety, panic, paranoia, delusions, heavy sedation, and catalepsy. Strong THC exposures and associated hallucinogenic and aversive effects have been especially associated with cannabis edibles.
In Table 5, the approximately $85 billion fine chemical market is subdivided into major applications according to their relevance: fine chemicals for pharmaceuticals, agrochemicals, and specialty chemicals outside life sciences. Furthermore, a distinction is made between captive (in-house) production and merchant market. Pharmaceutical fine chemicals (PFCs) account for two-thirds of the total. Out of the PFC value of $55 billion, about $23 billion (~40%) are traded, and $32 billion (~60%) are the production value of the pharma industry's in-house production. Within life science products, fine chemicals for agro and veterinary drugs follow in importance. The production value for fine chemicals used for specialty chemicals other than pharmaceuticals and agrochemicals is estimated at $15 billion. As the leading specialty chemical companies (Akzo Nobel, Dow, DuPont, Evonik, Chemtura and Mitsubishi) are backward-integrated, the share of in-house production is estimated at 75%, leaving a merchant market of approximately $5 billion.
=== Material === Material selection is the most important part for designing artificial skin. It needs to be biocompatible with the body while having adequate properties for adequate function. Human skin is made of type I collagen, elastin, and glycosaminoglycan. The artificial skin by Integra is made of a copolymer composed of collagen and glycosaminoglycan. Collagen is a hydrophilic polymer whose degradation and stiffness can be controlled by the degree of cross linking. However, it can be brittle and susceptible to breakdown by the enzyme collagenase. In order to make the material tougher and more resistant, a copolymer is formed with glycosaminoglycan (GAG). GAGs are long polysaccharides that act as shock absorbers. Collagen-GAG (CG) matrices have a higher modulus of elasticity and energy needed to fracture than collagen alone, making it a more ideal material. An outer layer of silicone is normally applied to the matrix in order to serve as a protective layer. Another material that can be used in synthetic skin is elastin. Elastin has a similar effect to GAG as it reduces the tensile strength and compressive modulus of the material while increasing its toughness.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.